FDA found microbial contamination risks and data integrity failures at Fareva Morton Grove's OTC drug manufacturing.
What happened
FDA inspected Fareva Morton Grove's drug manufacturing facility at 6901 Golf Road, Morton Grove, Illinois, from August 4 to 12, 2025. FDA found that a manufacturing system used to make OTC drugs was not suitably designed or controlled, had dead-legs (pipe sections where fluid can stagnate) that can harbor microbes, and repeatedly failed a specification; Pseudomonas aeruginosa and Serratia marcescens were found in the system. FDA also found that required microbial identification testing was not done for each batch and that microbiology records were incomplete, including a counted plate with 20 colony-forming units (CFUs) discarded without recording the result.
What FDA found
The company used a manufacturing system that was not suitably designed or controlled, had dead-legs (pipe sections where fluid can stagnate) that can harbor microbes, and repeatedly failed a specification; one qualification study had mostly failing samples, yet it was approved.
21 CFR 211.63The company did not perform required identification of all gram-negative rods found in drug product samples since January 2025, despite an increase in colony-forming units.
21 CFR 211.165(b)The company did not contemporaneously record negative microbiology plates, automatically entered zero for blank entries, discarded a plate with 20 colony-forming units (CFUs) without recording the count, and could not provide complete microbial sampling results.
21 CFR 211.194(a)
What FDA wants
FDA tells Fareva to correct the violations promptly and respond in writing within 15 working days with remediation plans, risk assessments, and independent assessments of its laboratory and documentation systems.
Who should pay attention
- companies whose OTC drugs are made at this site
- brand owners distributing drugs manufactured by Fareva Morton Grove in the U.S.
- quality teams responsible for microbial testing and data integrity at contract manufacturers
This is a summary. Read the original letter on fda.gov.